Stock N1BI34 NEUROCRINE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Neurocrine Biosciences, Inc. Sao Paulo

Equities

N1BI34

BRN1BIBDR009

Market Closed - Sao Paulo
Other stock markets
 08:33:54 26/06/2024 pm IST 		5-day change 1st Jan Change
37 BRL +8.00% Intraday chart for Neurocrine Biosciences, Inc. +2.78% +14.55%
13/06 Transcript : Neurocrine Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-13-2024 10:40 AM
05/06 Transcript : Neurocrine Biosciences, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 02:30 PM

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Transcript : Neurocrine Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-13-2024 10:40 AM
Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer
AQ
Transcript : Neurocrine Biosciences, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 02:30 PM
Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
PR
Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
CI
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
PR
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
PR
Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
CI
Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing
MT
Neurocrine Biosciences to Participate at Investor Conferences in June
PR
Neurocrine Biosciences to Present New Phase 3 CAHtalyst Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
AQ
Neurocrine Biosciences Says CEO Kevin Gorman Retiring
MT
Neurocrine founder-CEO Gorman to retire in October
RE
Neurocrine CEO set to retire
RE
Neurocrine Biosciences Announces CEO Succession Plan
PR
Neurocrine Biosciences, Inc. Announces Dr. Kyle Gano as Director, Effective October 11, 2024
CI
Neurocrine Biosciences Announces CEO Changes
CI
UBS Raises Price Target on Neurocrine Biosciences to $193 From $174, Maintains Buy Rating
MT
Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
PR
Neurocrine Biosciences Insider Sold Shares Worth $297,860, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. N1BI34 Stock
  5. News Neurocrine Biosciences, Inc.